Multiple cancer-related pathways including inhibition of tumor proliferation and metastasis; possible immunomodulation

This entry refers to a broad range of molecular targets and signaling pathways implicated in cancer, especially those whose modulation inhibits tumor proliferation and metastasis and potentially enhances anti-tumor immune responses. Such pathways include immune checkpoint molecules (e.g., PD-1, PD-L1, CTLA-4), immunosuppressive cell-surface proteins (e.g., CD47, CD73), cytokine receptors, and other mediators of tumor growth and immune regulation. Therapies targeting these molecules aim to restore anti-tumor immunity, disrupt cancer cell survival signals, block metastatic processes, or modulate the immunosuppressive tumor microenvironment. Because the term is not a recognized standard for a discrete molecular entity, all specifics must be tied to individual named targets within this class.

Mechanisms depend on the individual target/drug, but generally fall under immune checkpoint inhibition, immunomodulation, anti-proliferative action, and anti-metastatic action.